US5445832A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the preparation of microspheres made of a biodegradable polymeric material
Assignee: Debio Recherche Pharmaceutique SA
•
Filing: 1992-07-16
•
Granted: 1995-08-29
•
Expires: 2012-07-16
Abstract
Abstract The process is aimed at providing a composition designed for the sustained and controlled release of medicamentous peptide substances, obtained in the form of microspheres of a biodegradable polymeric material incorporating said medicamentous substance. It consists in converting first a water-soluble peptide or peptide salt into a water-insoluble peptide, respectively peptide salt. The following steps include preparing an organic-aqueous emulsion and then extracting the organic solvent in an excess of aqueous medium.
Inventors
- 👤 Piero Orsolini
- 👤 Frederic Heimgartner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:13
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/08; A61K38/16; A61K38/17; A61K38/22; A61K38/25; A61K38/09; A61K38/18; A61K38/1808; A61K38/19; A61K38/21; A61K38/2242; A61K38/2257; A61K38/23; A61K38/26; A61K38/28; A61K38/31; A61K38/33; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/1682; A61K9/1694; A61P; A61P5/00; A61P5/06; A61P5/24; C; C07; C07K; C07K7/00; C07K7/04; C07K7/23
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
153 words
A process for preparing a composition for the sustained and controlled release of a medicamentous peptide substance, said medicamentous peptide substance being a natural or synthetic poly peptide comprising from about 3 to about 45 amino acids, said composition being obtained in the form of microspheres of a biodegradable polymeric organic material incorporating said medicamentous substance, comprising the steps of: (a) converting a water soluble peptide or peptide salt into a corresponding water-insoluble peptide salt selected from the group consisting of the pamoate, stearate, and palmitate of said peptide; (b) suspending said water-insoluble peptide salt in an organic solvent containing a dissolved biodegradable polymeric organic material to form a suspension; (c) dispersing said organic suspension in an aqueous medium to form an aqueous emulsion, where the aqueous medium forms the continuous phase of the emulsion; (d) transferring said emulsion into an excess of an aqueous medium, and separating microspheres from the liquid phase.
Claim 2
Dependent Claim
153 words
A process for preparing a composition for the sustained and controlled release of a medicamentous peptide substance, said medicamentous peptide substance being a natural or synthetic poly peptide comprising from about 3 to about 45 amino acids, said composition being obtained in the form of microspheres of a biodegradable polymeric organic material incorporating said medicamentous substance, comprising the steps of: (a) converting a water soluble peptide or peptide salt into a corresponding water-insoluble peptide salt selected from the group consisting of the pamoate, stearate, and palmitate of said peptide; (b) suspending said water-insoluble peptide salt in an organic solvent containing a dissolved biodegradable polymeric organic material to form a suspension; (c) dispersing said organic suspension in an aqueous medium to form an aqueous emulsion, where the aqueous medium forms the continuous phase of the emulsion; (d) transferring said emulsion into an excess of an aqueous medium, and separating microspheres from the liquid phase.
Claim 3
Dependent Claim
26 words
A process according to claim 1 wherein before transferring said emulsion into an excess of aqueous medium, a partial evaporation of organic medium is carried out.
Claim 4
Dependent Claim
61 words
A process according to one of claims 1 or 2, wherein the medicamentous substance is selected from the group consisting of oxytocin, vasopressin, corticotrophin, calcitonin, epidermal growth factor (EGF), prolactin, inhibitin, interferon, somatoststin, insulin, glucagon, auricular natriuretic factor (ANF), endorphin, a renin inhibitor, luteinizing hormone-releasing hormone (LHRH), growth hormone releasing hormone (GHRH), peptide T, their synthetic analogues and their synthetic homologues.
Claim 5
Dependent Claim
55 words
A process according to one of claims 1 or 2 wherein the medicamentous substance is selected from the group consisting of LHRH, somatostatin, one of their synthetic analogues or homologues, ##STR3## Ac-DNal-DpCl-Phe-DPal-Ser-Tyr-DCit-Leu-Arg-Pro-DAla-NH 2 , (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 , (pyro) Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH 2 , (pyro) Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-Gly-NHR 1 and (pyro) Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-Gly- NHR 1 , (R 1 =lower alkyl).
Claim 6
Dependent Claim
39 words
A process according to one of claims 1 or 2 wherein the biodegradable polymeric material is selected from the group consisting of polylactides, polyglycolides, copolymers of lactic and glycolic acids, polyesters, polyalkylene fumarate, polyalkylene succinate, polyorthoesters, polyacetals and polyanhydrides.
Claim 7
Dependent Claim
49 words
A process according to claim 5 wherein the polymeric material is a copolymer of lactic and glycolic acids, wherein the molar ratio of lactic to glycolic residues, respectively, ranges from 45:55 to 90:10, and wherein the lactic acid residues may be in either the L or D, L configuration.
Claim 8
Dependent Claim
28 words
A process according to claim 6, wherein the polyalkylene fumarate or polyalkylene succinate is selected from the group consisting of poly-1,4-butylene--succinates, poly-2,3-butylene succinates poly-1,4-butylene fumarates and poly-2,3-butylene fumarates.
References Cited (Backward Citations)
US4010125A
Cited
US4622244A
Cited
US4675189A
Cited
EP0052510B1
Cited
EP0058481A1
Cited
US4767628A
Cited
US4767628B1
Cited
US4954298A
Cited
EP0204476A1
Cited
EP0211267A2
Cited
EP0251476A1
Cited
EP0302582A1
Cited
US5192741A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-08-28 | 1999-02-27 | 1999-08-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-08-28 | 2003-02-27 | 2003-08-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-08-28 | 2007-02-27 | 2007-08-29 | $7700.00 | Window Closed / Lapsed |